The earnings call presented a mixed outlook. While there were significant advancements in product development and strategic initiatives to counteract capital sales challenges, revenue fell short of expectations due to NIH funding uncertainties. The company's strong cash position and innovation roadmap progress are positives, but the lack of financial guidance and increased operating expenses indicate ongoing challenges.

Company Guidance -

Q3 2025

During the Quantum-Si Q2 2025 earnings call, the company provided guidance reflecting both challenges and strategic initiatives. Revenue for the quarter was $591,000, with consumable purchases slightly exceeding expectations despite a near halt in capital purchases by U.S. academic labs due to NIH funding uncertainties. The company more than doubled its funnel of opportunities in pharma and biotech, from approximately 30 at the end of Q1 to over 60 by the end of Q2. Gross profit was reported at $351,000 with a gross margin of 59%. Operating expenses were tightly controlled, with GAAP total operating expenses at $30.5 million, slightly higher than the previous year, while adjusted operating expenses were $23.8 million, showcasing efficient cost management. The company revised its annual estimate for adjusted operating expenses to $98 million or less, maintaining a strong cash position of $214.2 million as of June 30, 2025. Quantum-Si introduced new instrument acquisition models to address capital sales headwinds, aiming to grow its installed base and capture more consumable revenue. The company remains confident in its long-term opportunities in proteomics, with a strong innovation pipeline, including the upcoming launch of its version 4 sequencing kit within the quarter, and the Proteus development program on track for a 2026 launch.

Doubling of Pharma and Biotech Opportunity Funnel

Quantum-Si more than doubled its funnel of opportunities in the pharma and biotech sectors from 30 to over 60 opportunities by the end of Q2 2025.

Launch of Expanded Instrument Acquisition Options

To address capital sales headwinds, Quantum-Si launched new instrument acquisition options that do not require upfront capital purchase, leading to initial customer acquisition using this model.

Progress on Innovation Roadmap

The company is on track to launch the version 4 sequencing kit and version 3 library preparation kit, with significant improvements in sample processing and detection capabilities.

Advancements in Proteus Development Program

Key milestones in the Proteus program include successful demonstrations of new fluorescent dyes and wafer-scale surface chemistry processing, setting a foundation for future commercialization.

AI-Driven Amino Acid Recognizer Design

Quantum-Si achieved a significant milestone by using AI to design an amino acid recognizer, speeding up the development process and enhancing proteome coverage potential.

Strong Cash Position

Quantum-Si ended Q2 2025 with $214.2 million in cash, cash equivalents, and investments, with a runway extending into Q2 2028.

Quantum-Si (QSI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

QSI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.13 / -	-0.18	―	―	―
Aug 05, 2025	2025 (Q2)	-0.14 / -0.16	-0.16	0.00% (0.00)	―
May 15, 2025	2025 (Q1)	-0.15 / -0.11	-0.14	21.43% (+0.03)	―
Mar 03, 2025	2024 (Q4)	-0.18 / -0.23	-0.16	-43.75% (-0.07)	―
Nov 12, 2024	2024 (Q3)	-0.20 / -0.18	-0.17	-5.88% (>-0.01)	―
Aug 07, 2024	2024 (Q2)	-0.18 / -0.16	-0.18	11.11% (+0.02)	―
May 09, 2024	2024 (Q1)	-0.20 / -0.14	-0.17	17.65% (+0.03)	―
Feb 29, 2024	2023 (Q4)	-0.17 / -0.16	-0.24	33.33% (+0.08)	―
Nov 09, 2023	2023 (Q3)	-0.18 / -0.17	-0.23	26.09% (+0.06)	―
Aug 07, 2023	2023 (Q2)	-0.17 / -0.18	-0.23	21.74% (+0.05)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

QSI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$1.44	$1.37	-4.86%
May 15, 2025	$1.48	$1.48	0.00%
Mar 03, 2025	$1.30	$1.38	+6.15%
Nov 12, 2024	$1.00	$0.78	-22.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Quantum-Si (QSI) report earnings?

Quantum-Si (QSI) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Quantum-Si (QSI) earnings time?

Quantum-Si (QSI) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is QSI EPS forecast?

QSI EPS forecast for the fiscal quarter 2025 (Q3) is -0.13.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing